Royalty Pharma plc (RPRX)

NASDAQ: RPRX · Real-Time Price · USD

37.01

+0.34 (0.93%)

Oct 30, 2025, 3:13 PM EDT - Market open

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2014 - 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2014 - 2020
Cystic Fibrosis Franchise Revenue	811.37M	826.21M	Log In	Log In	Log In	Upgrade
Evrysdi Revenue	215.26M	224.43M	Log In	Log In	Log In	Upgrade
Tremfya Revenue	149.35M	147.14M	Log In	Log In	Log In	Upgrade
Trelegy Revenue	147.65M	146.92M	Log In	Log In	Log In	Upgrade
Tysabri Revenue	122.59M	124.82M	Log In	Log In	Log In	Upgrade
Imbruvica Revenue	-	131.09M	Log In	Log In	Log In	Upgrade
Xtandi Revenue	-	-	Log In	Log In	Log In	Upgrade
Promacta Revenue	-	-	Log In	Log In	Log In	Upgrade
Other Products Revenue	606.04M	548.82M	Log In	Log In	Log In	Upgrade
Total Income from Financial Royalty Assets	2.18B	2.15B	Log In	Log In	Log In	Upgrade
Revenue from Intangible Royalty Assets	-	-	Log In	Log In	Log In	Upgrade
Other Royalty Income	-	-	Log In	Log In	Log In	Upgrade
Other Royalty Income and Revenue	120.32M	114.15M	Log In	Log In	Log In	Upgrade
Revenue (Other)	-	-224.43M	Log In	Log In	Log In	Upgrade
Revenue (Total)	-	2.26B	Log In	Log In	Log In	Upgrade

Key Performance Indicators

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2014 - 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2014 - 2020
Portfolio Receipts	3.04B	2.80B	Log In	Log In	Log In	Upgrade

Updated Aug 6, 2025. Data Source: Fiscal.ai.